Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.07
ARRY's Cash to Debt is ranked higher than
57% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. ARRY: 1.07 )
ARRY' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 1.07

Equity to Asset -0.17
ARRY's Equity to Asset is ranked lower than
52% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ARRY: -0.17 )
ARRY' s 10-Year Equity to Asset Range
Min: -1.55   Max: 0.93
Current: -0.17

-1.55
0.93
F-Score: 4
Z-Score: -6.27
M-Score: -1.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -56.83
ARRY's Operating margin (%) is ranked higher than
73% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. ARRY: -56.83 )
ARRY' s 10-Year Operating margin (%) Range
Min: -410.11   Max: -12.98
Current: -56.83

-410.11
-12.98
Net-margin (%) -89.02
ARRY's Net-margin (%) is ranked higher than
70% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. ARRY: -89.02 )
ARRY' s 10-Year Net-margin (%) Range
Min: -511.63   Max: -12.77
Current: -89.02

-511.63
-12.77
ROA (%) -45.55
ARRY's ROA (%) is ranked higher than
62% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. ARRY: -45.55 )
ARRY' s 10-Year ROA (%) Range
Min: -134.46   Max: -4.15
Current: -45.55

-134.46
-4.15
ROC (Joel Greenblatt) (%) -393.49
ARRY's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. ARRY: -393.49 )
ARRY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -393.49   Max: -16.66
Current: -393.49

-393.49
-16.66
Revenue Growth (%) -15.30
ARRY's Revenue Growth (%) is ranked higher than
66% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. ARRY: -15.30 )
ARRY' s 10-Year Revenue Growth (%) Range
Min: -23.5   Max: 39.4
Current: -15.3

-23.5
39.4
EBITDA Growth (%) -27.10
ARRY's EBITDA Growth (%) is ranked higher than
61% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. ARRY: -27.10 )
ARRY' s 10-Year EBITDA Growth (%) Range
Min: -65.7   Max: 101.4
Current: -27.1

-65.7
101.4
EPS Growth (%) -28.40
ARRY's EPS Growth (%) is ranked higher than
63% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. ARRY: -28.40 )
ARRY' s 10-Year EPS Growth (%) Range
Min: -50.5   Max: 55.7
Current: -28.4

-50.5
55.7
» ARRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

ARRY Guru Trades in Q2 2013

Steven Cohen Sold Out
Jim Simons Sold Out
» More
Q3 2013

ARRY Guru Trades in Q3 2013

Jim Simons 586,752 sh (New)
» More
Q4 2013

ARRY Guru Trades in Q4 2013

Jim Simons 363,852 sh (-37.99%)
» More
Q1 2014

ARRY Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARRY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2011-12-31 Sold Out 0.0024%$1.77 - $2.83 $ 4.1883%0
George Soros 2011-12-31 Sold Out 0.0008%$1.77 - $2.83 $ 4.1883%0
George Soros 2011-09-30 New Buy$1.99 - $2.62 $ 4.1887%22400
George Soros 2011-06-30 Sold Out $2.06 - $3.21 $ 4.1855%0
Jean-Marie Eveillard 2011-06-30 Add 150%$2.06 - $3.21 $ 4.1855%250000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 8.10
ARRY's P/S is ranked higher than
82% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. ARRY: 8.10 )
ARRY' s 10-Year P/S Range
Min: 1.43   Max: 16.57
Current: 8.1

1.43
16.57
EV-to-EBIT -9.00
ARRY's EV-to-EBIT is ranked lower than
53% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARRY: -9.00 )
ARRY' s 10-Year EV-to-EBIT Range
Min: 6082.4   Max: 8002.5
Current: -9

6082.4
8002.5
Current Ratio 2.57
ARRY's Current Ratio is ranked higher than
64% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. ARRY: 2.57 )
ARRY' s 10-Year Current Ratio Range
Min: 0.81   Max: 7.86
Current: 2.57

0.81
7.86
Quick Ratio 2.57
ARRY's Quick Ratio is ranked higher than
66% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ARRY: 2.57 )
ARRY' s 10-Year Quick Ratio Range
Min: 0.81   Max: 7.55
Current: 2.57

0.81
7.55

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.40
ARRY's Price/Median PS Value is ranked higher than
78% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. ARRY: 1.40 )
ARRY' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 2.49
Current: 1.4

0.24
2.49
Forward Rate of Return (Yacktman) -57.58
ARRY's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. ARRY: -57.58 )
ARRY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -77.3   Max: -61
Current: -57.58

-77.3
-61

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AR2.Germany
Array BioPharma, Inc., is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across various therapeutic areas. The Company is evolving into a late-stage development company, with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib partnered with AstraZeneca, MEK162 partnered with Novartis, and danoprevir, an NS3 protease inhibitor, partnered with InterMune / Roche, having the potential to begin pivotal trials by the end of calendar year 2013. The Company's proprietary clinical programs include ARRY-520, ARRY-614, ARRY-797, and ARRY-502. The Company's internal drug discovery programs include inhibitors that target Trk receptors for the treatment of pain and G-protein-coupled receptor 119 for the treatment of diabetes. The Company competes with companies worldwide that are engaged in the research and discovery, licensing, development and commercialization of drug candidates, including large pharmaceutical companies with internal discovery and development functions, biotech companies with competing products in the therapeutic areas it is targeting and contract research organizations that perform many of the functions it performs under its collaborations. The Company is subject to substantial regulation by governmental agencies in the U.S. and other countries.
» More Articles for ARRY

Headlines

Articles On GuruFocus.com
comment on ARRY Mar 02 2013 
Re: ARRY Aug 29 2011 
Drug Penny Stock Aug 23 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,310 Shares Mar 16 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,403 Shares Feb 11 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,272 Shares Jan 13 2011 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,256 Shares Dec 10 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,220 Shares Nov 12 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,225 Shares Oct 13 2010 
Array BioPharma Inc. (ARRY) CFO Michael Carruthers sells 1,309 Shares Jul 23 2010 


More From Other Websites
Array BioPharma, Inc. (ARRY) Jumps: Stock Surges 10.7% Higher Jul 24 2014
Array BioPharma To Present At The Wells Fargo Securities 2014 Healthcare Conference Jun 11 2014
ARRAY BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 02 2014
Array BioPharma receives orphan status for kinase inhibitor Jun 02 2014
Two Array-Invented MEK Inhibitors Showcased At ASCO Jun 02 2014
Eight Analyst Stocks to Buy Under $10 for Big Upside May 31 2014
The Zacks Analyst Blog Highlights: Facebook, AT&T, Array BioPharma, Biogen Idec and Celgene May 30 2014
Array BioPharma Collaborates with Biogen May 29 2014
Array and BioPharma Biogen to collaborate in inhibitor discovery and development May 28 2014
ARRAY BIOPHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 28 2014
Array BioPharma Announces Drug Discovery Collaboration Agreement With Biogen Idec May 28 2014
Array BioPharma To Present At The Jefferies 2014 Global Healthcare Conference May 27 2014
Array BioPharma (ARRY) Presents at UBS Global Healthcare Conference (Transcript) May 20 2014
ARRAY BIOPHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... May 19 2014
Array BioPharma hires new Chief Scientific Officer, VP of R&D May 19 2014
Array BioPharma Announces Key Additions To Scientific Leadership May 19 2014
ARRAY BIOPHARMA INC Financials May 16 2014
Array Biopharma's (ARRY) CEO Ron Squarer Presents at Bank of America Merrill Lynch Health Care... May 14 2014
Array BioPharma Announces Clinical Data Presentations At The 2014 ASCO Annual Meeting May 14 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide